Targeting the purinergic pathway in breast cancer and its therapeutic applications.
Targeting the purinergic pathway in breast cancer and its therapeutic applications.
复制标题
乳腺癌嘌呤能通路的靶向治疗及其应用。
DOI：
10.1007/s11302-020-09760-9
复制
发表时间：
2021-06
影响因子：
3.5
通讯作者：
de Resende E Silva DT
中科院分区：
文献类型：
--
作者：
de Araújo JB;Kerkhoff VV;de Oliveira Maciel SFV;de Resende E Silva DT
乳腺癌（BC）是女性最常见的死亡原因，是一个全球性的公共卫生问题。在这里，我们的目的是讨论嘌呤能系统和BC之间的相关性，识别治疗靶点。为此，我们分析了细胞外核苷酸和核苷与嘌呤能受体P1和P2的相互作用，以及外核苷酸酶（CD39和CD73）对肿瘤进展的影响。进行了全面的文献检索。本综述的相关文章可在PubMed、Scielo、Lilacs和ScienceDirect数据库中找到。在P1受体中，A1、A2A和A2B受体参与了BC的增殖和侵袭，而A3受体与肿瘤生长的抑制有关。在P2受体中，P2X7具有双重功能。当短时间激活时，它促进转移，但当长时间激活时，它与BC细胞死亡有关。P2Y2和P2Y6受体与BC的增殖和侵袭性有关。此外，CD39和CD73在BC中的高表达与预后不良密切相关。与BC相关的受体和外核苷酸酶成为可能的治疗靶点。已经发现几种嘌呤能途径参与BC细胞的存活和进展。在这篇综述中，除了分析所涉及的途径，我们回顾了已经研究的治疗干预BC相关的嘌呤能系统，以及其他可能的治疗靶点。
Breast cancer (BC) is the most frequent cause of death among women, representing a global public health problem. Here, we aimed to discuss the correlation between the purinergic system and BC, recognizing therapeutic targets. For this, we analyzed the interaction of extracellular nucleotides and nucleosides with the purinergic receptors P1 and P2, as well as the influence of ectonucleotidase enzymes (CD39 and CD73) on tumor progression. A comprehensive bibliographic search was carried out. The relevant articles for this review were found in the PubMed, Scielo, Lilacs, and ScienceDirect databases. It was observed that among the P1 receptors, the A1, A2A, and A2B receptors are involved in the proliferation and invasion of BC, while the A3 receptor is related to the inhibition of tumor growth. Among the P2 receptors, the P2X7 has a dual function. When activated for a short time, it promotes metastasis, but when activated for long periods, it is related to BC cell death. P2Y2 and P2Y6 receptors are related to BC proliferation and invasiveness. Also, the high expression of CD39 and CD73 in BC is strongly related to a worse prognosis. The receptors and ectonucleotidases involved with BC become possible therapeutic targets. Several purinergic pathways have been found to be involved in BC cell survival and progression. In this review, in addition to analyzing the pathways involved, we reviewed the therapeutic interventions already studied for BC related to the purinergic system, as well as to other possible therapeutic targets.
登录
查看更多内容
影响因子：
2.9
作者：
Albini A;Bruno A;Gallo C;Pajardi G;Noonan DM;Dallaglio K
通讯作者：
Dallaglio K
影响因子：
13.6
作者：
Antonioli L;Pacher P;Vizi ES;Haskó G
通讯作者：
Haskó G
影响因子：
6.6
作者：
Azimi, Iman;Beilby, Hannah;Monteith, Gregory R.
通讯作者：
Monteith, Gregory R.
影响因子：
8.7
作者：
Allard B;Longhi MS;Robson SC;Stagg J
通讯作者：
Stagg J
影响因子：
3.9
作者：
Bilbao, Paola Scodelaro;Boland, Ricardo;Santillan, Graciela
通讯作者：
Santillan, Graciela